GASTRICHIP: D2 resection and hyperthermic intraperitoneal chemotherapy in locally advanced gastric carcinoma: A randomized and multicenter phase III study

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Glehen, Olivier ^a,b   Passot, Guillaume ^a,b   Villeneuve, Laurent ^c,d,e   Vaudoyer, Delphine ^a,b   Bin Dorel, Sylvie ^c,d,e   Boschetti, Gilles ^a   Piaton, Eric ^c   Garofalo, Alfredo ^f  

^a CENTRE HOSPITALIER LYON SUD   (France)

^b UNIVERSITÉ CLAUDE BERNARD LYON 1   (France)

^c HOSPICES CIVILS DE LYON   (France)

^d UNIVERSITÉ DE LYON   (France)

^e UNIVERSITÉ LYON 1   (France)

^f Reparto di Chirurgia Oncologica Institutio Nazionale Tumori Regina   (Italy)

Author keywords

Gastric adenocarcinoma; Hyperthermic intraperitoneal chemotherapy; Oxaliplatin; Peritoneal carcinomatosis

Indexed keywords

OXALIPLATIN; CARCINOEMBRYONIC ANTIGEN; CISPLATIN; FOLINIC ACID; MITOMYCIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; ASCITES FLUID CYTOLOGY; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER STAGING; CONTROLLED STUDY; FOLLOW UP; GASTRECTOMY; HUMAN; HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MORBIDITY; MULTICENTER STUDY; OPEN STUDY; OVERALL SURVIVAL; PERIOPERATIVE PERIOD; PERITONEUM LAVAGE; PHASE 3 CLINICAL TRIAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RECURRENCE FREE SURVIVAL; RECURRENCE RISK; STOMACH CARCINOMA; SURVIVAL TIME; ADJUVANT CHEMOTHERAPY; CANCER CELL; CANCER INCIDENCE; CANCER SURGERY; CAUCASIAN; COMPUTER ASSISTED TOMOGRAPHY; CYTOLOGY; CYTOREDUCTIVE SURGERY; EUROPEAN; HYPERTHERMIC THERAPY; INCIDENCE; LAPAROSCOPY; LYMPH NODE; PERITONEAL CAVITY; RECURRENT DISEASE; SEROSA; SIGNET RING CARCINOMA; STOMACH CANCER; SURGICAL TECHNIQUE; SURVIVAL RATE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; EUROPE; GASTRECTOMY; HUMANS; HYPERTHERMIA, INDUCED; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; ORGANOPLATINUM COMPOUNDS; PERITONEAL NEOPLASMS; PROSPECTIVE STUDIES; STOMACH NEOPLASMS; YOUNG ADULT;

EID: 84899113246     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-183     Document Type: Article

References (58)

1. Institut National du Cancer (INCa) Bases PMSI MCO Médecine Chirurgie Obstétrique 2010, Boulogne-Billancourt: Institut National du Cancer (INCa), Institut National du Cancer (INCa).
2. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006, 24(14):2137-2150. 10.1200/JCO.2005.05.2308, 16682732.
3. Jackson C, Cunningham D, Oliveira J. Gastric cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009, 20(Suppl 4):34-36.
4. Memon MA, Subramanya MS, Khan S, Hossain MB, Osland E, Memon B. Meta-analysis of D1 versus D2 gastrectomy for gastric adenocarcinoma. Ann Surg 2011, 253(5):900-911. 10.1097/SLA.0b013e318212bff6, 21394009.
5. Bonenkamp JJ, Hermans J, Sasako M, van de Velde CJ, Welvaart K, Songun I, Meyer S, Plukker JT, Van Elk P, Obertop H, Gouma DJ, van Lanschot JJ, van Taat CW, de Graaf PW, von Meyenfeldt MF, Tilanus H, . Dutch Gastric Cancer Group Extended lymph-node dissection for gastric cancer. N Engl J Med 1999, 340(12):908-914. 10.1056/NEJM199903253401202, 10089184, Dutch Gastric Cancer Group.
6. Cuschieri A, Fayers P, Fielding J, Craven J, Bancewicz J, Joypaul V, Cook P. Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial. The Surgical Cooperative Group. Lancet 1996, 347(9007):995-999. 10.1016/S0140-6736(96)90144-0, 8606613.
7. Edwards P, Blackshaw GR, Lewis WG, Barry JD, Allison MC, Jones DR. Prospective comparison of D1 vs modified D2 gastrectomy for carcinoma. Br J Cancer 2004, 90(10):1888-1892. 10.1038/sj.bjc.6601790, 2409472, 15138467.
8. Degiuli M, Sasako M, Ponti A, Calvo F. Survival results of a multicentre phase II study to evaluate D2 gastrectomy for gastric cancer. Br J Cancer 2004, 90(9):1727-1732. 2409745, 15150592.
9. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ, . MAGIC Trial Participants Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006, 355(1):11-20. 10.1056/NEJMoa055531, 16822992, MAGIC Trial Participants.
10. Ychou M, Boige V, Pignon JP, Conroy T, Bouche O, Lebreton G, Ducourtieux M, Bedenne L, Fabre JM, Saint-Aubert B, Genève J, Lasser P, Rougier P. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol 2011, 29(13):1715-1721. 10.1200/JCO.2010.33.0597, 21444866.
11. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, Haller DG, Ajani JA, Gunderson LL, Jessup JM, Martenson JA. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001, 345(10):725-730. 10.1056/NEJMoa010187, 11547741.
12. Dahan L, Atlan D, Bouche O, Mitry E, Ries P, Artru P, Richard K, Lledo G, Nguyen T, Rougier P, Seitz JF. Postoperative chemoradiotherapy after surgical resection of gastric adenocarcinoma: can LV5FU2 reduce the toxic effects of the Macdonald regimen? A report on 23 patients. Gastroenterol Clin Biol 2005, 29(1):11-15. 10.1016/S0399-8320(05)80688-8, 15738890.
13. Kim S, Lim DH, Lee J, Kang WK, Macdonald JS, Park CH, Park SH, Lee SH, Kim K, Park JO, Kim WS, Jung CW, Park YS, Im YH, Sohn TS, Noh JH, Heo JS, Kim YI, Park CK, Park K. An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach. Int J Radiat Oncol Biol Phys 2005, 63(5):1279-1285. 10.1016/j.ijrobp.2005.05.005, 16099596.
14. Paoletti X, Oba K, Burzykowski T, Michiels S, Ohashi Y, Pignon JP, Rougier P, Sakamoto J, Sargent D, Sasako M, Van Cutsem E, Buyse M, . GASTRIC (Global Advanced/Adjuvant Stomach Tumor Research International Collaboration) Group Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA 2010, 303(17):1729-1737. GASTRIC (Global Advanced/Adjuvant Stomach Tumor Research International Collaboration) Group.
15. Yoo CH, Noh SH, Shin DW, Choi SH, Min JS. Recurrence following curative resection for gastric carcinoma. Br J Surg 2000, 87(2):236-242. 10.1046/j.1365-2168.2000.01360.x, 10671934.
16. Maehara Y, Hasuda S, Koga T, Tokunaga E, Kakeji Y, Sugimachi K. Postoperative outcome and sites of recurrence in patients following curative resection of gastric cancer. Br J Surg 2000, 87(3):353-357. 10.1046/j.1365-2168.2000.01358.x, 10718807.
17. Wu CW, Lo SS, Shen KH, Hsieh MC, Chen JH, Chiang JH, Lin HJ, Li AF, Lui WY. Incidence and factors associated with recurrence patterns after intended curative surgery for gastric cancer. World J Surg 2003, 27(2):153-158.
18. Yonemura Y, Bandou E, Kinoshita K, Kawamura T, Takahashi S, Endou Y, Sasaki T. Effective therapy for peritoneal dissemination in gastric cancer. Surg Oncol Clin N Am 2003, 12(3):635-648. 10.1016/S1055-3207(03)00035-8, 14567022.
19. Bentrem D, Wilton A, Mazumdar M, Brennan M, Coit D. The value of peritoneal cytology as a preoperative predictor in patients with gastric carcinoma undergoing a curative resection. Ann Surg Oncol 2005, 12(5):347-353. 10.1245/ASO.2005.03.065, 15915368.
20. Homma Y, Ushida S, Yamada M, Kobayashi H, Suzuki K. Positive peritoneal washing cytology in multiple cavities can predict poor prognosis of advanced gastric cancer patients. Ann Surg Oncol 2009, 17(2):455-460.
21. Marutsuka T, Shimada S, Shiomori K, Hayashi N, Yagi Y, Yamane T, Ogawa M. Mechanisms of peritoneal metastasis after operation for non-serosa-invasive gastric carcinoma: an ultrarapid detection system for intraperitoneal free cancer cells and a prophylactic strategy for peritoneal metastasis. Clin Cancer Res 2003, 9(2):678-685.
22. Piessen G, Messager M, Leteurtre E, Jean-Pierre T, Mariette C. Signet ring cell histology is an independent predictor of poor prognosis in gastric adenocarcinoma regardless of tumoral clinical presentation. Ann Surg 2009, 250(6):878-887. 10.1097/SLA.0b013e3181b21c7b, 19855261.
23. Glehen O, Gilly FN, Boutitie F, Bereder JM, Quenet F, Sideris L, Mansvelt B, Lorimier G, Msika S, Elias D. Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy: a multi-institutional study of 1,290 patients. Cancer 2010, 116(24):5608-5618. 10.1002/cncr.25356, 20737573.
24. Elias D, Gilly F, Boutitie F, Quenet F, Bereder JM, Mansvelt B, Lorimier G, Dube P, Glehen O. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol 2010, 28(1):63-68. 10.1200/JCO.2009.23.9285, 19917863.
25. Yan TD, Deraco M, Baratti D, Kusamura S, Elias D, Glehen O, Gilly FN, Levine EA, Shen P, Mohamed F, Moran BJ, Morris DL, Chua TC, Piso P, Sugarbaker PH. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol 2009, 27(36):6237-6242. 10.1200/JCO.2009.23.9640, 19917862.
26. Sugarbaker PH. New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome?. Lancet Oncol 2006, 7(1):69-76. 10.1016/S1470-2045(05)70539-8, 16389186.
27. Barlogie B, Corry PM, Drewinko B. In vitro thermochemotherapy of human colon cancer cells with cis-dichlorodiammineplatinum (II) and mitomycin C. Cancer Res 1980, 40(4):1165-1168.
28. Glehen O, Beaujard AC, Arvieux C, Huber O, Gilly FN. Les carcinoses péritonéales. Traitement chirurgical, péritonectomies et chimiohyperthermie intrapéritonéale. Gastroenterol Clin Biol 2002, 26(3):210-215.
29. Pestieau SR, Belliveau JF, Griffin H, Stuart OA, Sugarbaker PH. Pharmacokinetics of intraperitoneal oxaliplatin: experimental studies. J Surg Oncol 2001, 76(2):106-114. 10.1002/1096-9098(200102)76:2<106::AID-JSO1020>3.0.CO;2-E, 11223836.
30. Glehen O, Gilly FN, Arvieux C, Cotte E, Boutitie F, Mansvelt B, Bereder JM, Lorimier G, Quenet F, Elias D. Peritoneal carcinomatosis from gastric cancer: a multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy. Ann Surg Oncol 2010, 17(9):2370-2377. 10.1245/s10434-010-1039-7, 20336386.
31. Yang XJ, Huang CQ, Suo T, Mei LJ, Yang GL, Cheng FL, Zhou YF, Xiong B, Yonemura Y, Li Y. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial. Ann Surg Oncol 2011, 18(6):1575-1581. 10.1245/s10434-011-1631-5, 3087875, 21431408.
32. Yu W, Whang I, Suh I, Averbach A, Chang D, Sugarbaker PH. Prospective randomized trial of early postoperative intraperitoneal chemotherapy as an adjuvant to resectable gastric cancer. Ann Surg 1998, 228(3):347-354. 10.1097/00000658-199809000-00007, 1191489, 9742917.
33. Xu DZ, Zhan YQ, Sun XW, Cao SM, Geng QR. Meta-analysis of intraperitoneal chemotherapy for gastric cancer. World J Gastroenterol 2004, 10(18):2727-2730.
34. Yu W, Whang I, Chung HY, Averbach A, Sugarbaker PH. Indications for early postoperative intraperitoneal chemotherapy of advanced gastric cancer: results of a prospective randomized trial. World J Surg 2001, 25(8):985-990. 10.1007/s00268-001-0067-7, 11571980.
35. Fujimoto S, Takahashi M, Mutou T, Kobayashi K, Toyosawa T. Successful intraperitoneal hyperthermic chemoperfusion for the prevention of postoperative peritoneal recurrence in patients with advanced gastric carcinoma. Cancer 1999, 85(3):529-534. 10.1002/(SICI)1097-0142(19990201)85:3<529::AID-CNCR3>3.0.CO;2-9, 10091726.
36. Yonemura Y, de Aretxabala X, Fujimura T, Fushida S, Katayama K, Bandou E, Sugiyama K, Kawamura T, Kinoshita K, Endou Y, Sasaki T. Intraoperative chemohyperthermic peritoneal perfusion as an adjuvant to gastric cancer: final results of a randomized controlled study. Hepatogastroenterology 2001, 48(42):1776-1782.
37. Kim JY, Bae HS. A controlled clinical study of serosa-invasive gastric carcinoma patients who underwent surgery plus intraperitoneal hyperthermo-chemo-perfusion (IHCP). Gastric Cancer 2001, 4(1):27-33. 10.1007/s101200100013, 11706624.
38. Yan TD, Black D, Sugarbaker PH, Zhu J, Yonemura Y, Petrou G, Morris DL. A systematic review and meta-analysis of the randomized controlled trials on adjuvant intraperitoneal chemotherapy for resectable gastric cancer. Ann Surg Oncol 2007, 14(10):2702-2713. 10.1245/s10434-007-9487-4, 17653801.
39. Coccolini F, Cotte E, Glehen O, Lotti M, Poiasina E, Catena F, Yonemura Y, Ansaloni L. Intraperitoneal chemotherapy in advanced gastric cancer. Meta-analysis of randomized trials. Eur J Surg Oncol In press.
40. Bonenkamp JJ, Songun I, Hermans J, Sasako M, Welvaart K, Plukker JT, van Elk P, Obertop H, Gouma DJ, Taat CW, et al. Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients. Lancet 1995, 345(8952):745-748. 10.1016/S0140-6736(95)90637-1, 7891484.
41. Siewert JR, Feith M, Stein HJ. Biologic and clinical variations of adenocarcinoma at the esophago-gastric junction: relevance of a topographic-anatomic subclassification. J Surg Oncol 2005, 90(3):139-146. discussion 146, 10.1002/jso.20218, 15895452.
42. Japanese Gastric Cancer A Japanese Classification of Gastric Carcinoma - 2nd English Edition. Gastric Cancer 1998, 1(1):10-24. Japanese Gastric Cancer A.
43. Kramar A, Bascoul-Mollevi C, Gourgou-Bourgade S. Règles d'arrêt précoce dans les essais cliniques basées sur une surveillance séquentielle des événements indésirables graves. Revue de Statistique Appliquée 2005, 53(4):49-59.
44. Bascoul-Mollevi C, Laplanche A, Le Deley MC, Kramar A. SAE: an R package for early stopping rules in clinical trials. Comput Methods Programs Biomed 2011, 104(2):243-248. 10.1016/j.cmpb.2011.05.005, 21741110.
45. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, Middleton G, Daniel F, Oates J, Norman AR. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008, 358(1):36-46. 10.1056/NEJMoa073149, 18172173.
46. Cotte E, Peyrat P, Piaton E, Chapuis F, Rivoire M, Glehen O, Arvieux C, Mabrut JY, Chipponi J, Gilly FN. Lack of prognostic significance of conventional peritoneal cytology in colorectal and gastric cancers: results of EVOCAPE 2 multicentre prospective study. Eur J Surg Oncol 2013, 39(7):707-714. 10.1016/j.ejso.2013.03.021, 23601984.
47. Bao G, Qiao Q, Zhao H, He X. Prognostic value of HMGB1 overexpression in resectable gastric adenocarcinomas. World J Surg Oncol 2010, 8:52. 10.1186/1477-7819-8-52, 2909949, 20579387.
48. Cavaliere F, Di Filippo F, Botti C, Cosimelli M, Giannarelli D, Aloe L, Arcuri E, Aromatario C, Consolo S, Callopoli A, Callopoli A, Laurenzi L, Tedesco M, Di Angelo P, Giunta S, Cavaliere R. Peritonectomy and hyperthermic antiblastic perfusion in the treatment of peritoneal carcinomatosis. Eur J Surg Oncol 2000, 26(5):486-491. 10.1053/ejso.1999.0927, 11016471.
49. Fujimura T, Yonemura Y, Fushida S, Urade M, Takegawa S, Kamata T, Sugiyama K, Hasegawa H, Katayama K, Miwa K, et al. Continuous hyperthermic peritoneal perfusion for the treatment of peritoneal dissemination in gastric cancers and subsequent second-look operation. Cancer 1990, 65(1):65-71. 10.1002/1097-0142(19900101)65:1<65::AID-CNCR2820650115>3.0.CO;2-L, 2104572.
50. Glehen O, Mithieux F, Osinsky D, Beaujard AC, Freyer G, Guertsch P, Francois Y, Peyrat P, Panteix G, Vignal J, Gilly FN. Surgery combined with peritonectomy procedures and intraperitoneal chemohyperthermia in abdominal cancers with peritoneal carcinomatosis: a phase II study. J Clin Oncol 2003, 21(5):799-806. 10.1200/JCO.2003.06.139, 12610177.
51. Okines AF, Ashley SE, Cunningham D, Oates J, Turner A, Webb J, Saffery C, Chua YJ, Chau I. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for advanced esophagogastric cancer: dose-finding study for the prospective multicenter, randomized, phase II/III REAL-3 trial. J Clin Oncol 2010, 28(25):3945-3950. 10.1200/JCO.2010.29.2847, 20679619.
52. Novotny AR, Schuhmacher C, Busch R, Kattan MW, Brennan MF, Siewert JR. Predicting individual survival after gastric cancer resection: validation of a U.S.-derived nomogram at a single high-volume center in Europe. Ann Surg 2006, 243(1):74-81. 10.1097/01.sla.0000194088.81126.85, 1449962, 16371739.
53. Cunningham SC, Kamangar F, Kim MP, Hammoud S, Haque R, Maitra A, Montgomery E, Heitmiller RE, Choti MA, Lillemoe KD, Cameron JL, Yeo CJ, Schulick RD. Survival after gastric adenocarcinoma resection: eighteen-year experience at a single institution. J Gastrointest Surg 2005, 9(5):718-725. 10.1016/j.gassur.2004.12.002, 15862270.
54. Messager M, Lefevre JH, Pichot-Delahaye V, Souadka A, Piessen G, Mariette C. The impact of perioperative chemotherapy on survival in patients with gastric signet ring cell adenocarcinoma: a multicenter comparative study. Ann Surg 2011, 254(5):684-693. discussion 693, 10.1097/SLA.0b013e3182352647, 22005144.
55. Macdonald S, Taghian AG. Prognostic factors for local control after breast conservation: does margin status still matter?. J Clin Oncol 2009, 27(30):4929-4930. 10.1200/JCO.2009.23.6679, 19720895.
56. Sugarbaker PH, Cunliffe WJ, Belliveau J, de Bruijn EA, Graves T, Mullins RE, Schlag P. Rationale for integrating early postoperative intraperitoneal chemotherapy into the surgical treatment of gastrointestinal cancer. Semin Oncol 1989, 16(4 Suppl 6):83-97.
57. Han TS, Kong SH, Lee HJ, Ahn HS, Hur K, Yu J, Kim WH, Yang HK. Dissemination of free cancer cells from the gastric lumen and from perigastric lymphovascular pedicles during radical gastric cancer surgery. Ann Surg Oncol 2011, 18(10):2818-2825. 10.1245/s10434-011-1620-8, 21455599.
58. Bonenkamp JJ, Songun I, Hermans J, van de Velde CJ. Prognostic value of positive cytology findings from abdominal washings in patients with gastric cancer. Br J Surg 1996, 83(5):672-674. 10.1002/bjs.1800830526, 8689216.